PRECISION BIOSCIENCES INC (DTIL)
D
Pipeline Grade
Financial Position (from SEC Filings)
$125.9M
Cash & Equivalents
$11.9M
Quarterly Burn Rate
32 mo
Est. Cash Runway
$226M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07254208 | A Long-term Observational Study in Participants Who Have Received PBGENE-HBV | OTHER | Enrolling By Invitation | 45 |
| NCT07429240 | PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) | PHASE2 | Recruiting | 18 |
| NCT06680232 | Phase 1 Study to Evaluate Safety and Antiviral Activity of PBGENE-HBV in Adult Patients With Chronic Hepatitis B | PHASE1 | Recruiting | 45 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-05-27 | 8-K | PRECISION BIOSCIENCES INC (DTIL) (CIK 0001357874) - EX-99.1 | EDGAR |